<DOC>
	<DOC>NCT03091569</DOC>
	<brief_summary>The primary objective of the study is to investigate whether topical Vitamin K application reduces the grade of erythema in comparison with a vehicle cream (placebo) through physicians' assessment and participant self-assessment. The secondary objectives of this study are to evaluate in this study population: effects of Vitamin K in reducing the burning sensation and local pain; effects of Vitamin K in reducing the erythema diameter; and the evaluation of participants' satisfaction related to the injection treatment.</brief_summary>
	<brief_title>Effects of Vitamin K on Redness Associated With Injection Site Reactions in Participants Treated With Plegridy</brief_title>
	<detailed_description />
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<criteria>Key RelapsingRemitting Multiple Sclerosis (RRMS) participants for which Plegridy is deemed necessary by the neurologist. Participants switching from other Disease Modifying Treatments (DMTs) will be eligible provided that Plegridy is administered at an injection site different from the previous one. Key Participants with other skin disorders Pregnancy or current breastfeeding Depression and other psychiatric disorders Unwillingness or inability to comply with the requirements of the protocol. NOTE: Other protocol defined Inclusion/Exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>